ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Embecta (EMBC)
Embecta stock price today, ATLAS forecast and fair value
Healthcare · Medical Instruments & Supplies · NASDAQ
$6.55▼ -3.68%
Prices as of Oct 27, 2026 · USD
Chance of rising in 1 month
48%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Embecta in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Embecta
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Embecta a 48% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between $5.95 and $7.13; in 9 out of 10, between $5.07 and $8.37. Estimated annual volatility is 52%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- $320M
- P/E ratio
- 3.7
- Dividend yield
- 4.89%
- 52-week high
- $14.91
- 52-week low
- $2.77
- Revenue (12 months)
- $1.0B
- Revenue growth (YoY)
- -3.8%
- Earnings growth (YoY)
- +20.9%
- Gross margin
- 62.6%
- Operating margin
- 27.4%
- Net margin
- 8.8%
- Return on equity
- -14.6%
- Free cash flow (12 months)
- $138M
- Beta
- 0.85
What this means
ATLAS does not publish a fair value for EMBC right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks EMBC has traded between $2.77 and $14.91. Today it is 56.1% below that high and 136% above its low.
On the business: revenue fell 3.8% year over year; net margin is 8.8%; it trades at 3.7 times earnings.
Its beta is 0.85: it moves roughly in line with the market.
About the company
Embecta Corp. is a medical device company focused on products and services that support diabetes management.
Want to see everything about Embecta?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Embecta do?
Embecta Corp. is a medical device company focused on products and services that support diabetes management.
What is the chance EMBC goes up next month?
48%: close to a coin flip. In half of the simulated outcomes, EMBC ends the month between $5.95 and $7.13.
How big is Embecta and what is its P/E ratio?
Embecta's market capitalization is $320M. Its price-to-earnings (P/E) ratio is 3.7: you pay $3.7 for each $1 of yearly earnings.
Does Embecta pay a dividend?
Yes. EMBC's current dividend yield is 4.89% at today's price ($6.55).
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer